Therapies prior to hematopoietic cell transplantation (HCT) have no effect on outcomes in patients with high-risk myelodysplastic syndromes (MDS), according to an abstract presented at ASH. In a study of 291 MDS patients (median age 55 years, range: 18-71), there was no difference in event-free survival (EFS) among different pre-HCT therapy groups, including untreated patients. Three-year EFS for chemotherapy, hypomethylating agents, chemo plus hypomethylating agents, and no prior therapy were 31.2%, 31.1%, 31.5%, and 43.4%, respectively (p>0.05). The authors concluded that high-risk MDS patients should be transplanted without delay, because additional therapy to achieve better disease control does not appear to lead to more favorable transplant outcomes.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Prior Therapy Does Not Affect Transplant Outcomes in High-Risk MDS
Dec 2013